Diabetic Biomarker

Skip to content

+902126592180 Üsküdar, İstanbul mehmetali@diabeticbiomarker.com

Email

Diabetic Biomarker

Procalcitonin as a Prognostic Diabetic Biomarker

Search for:

THE INVENTION POLICY

THE INVENTION POLICY

Seminar – Procalicitonin as a diabetic biomarker

Summary

The method is useful for performing in vitro diagnosis of pancreatic diabetes mellitus and/or pancreatic diabetes mellitus complications chosen from diabetic microangiopathy, retinopathy, … [Read More]

Invention Details

There are currently 415 million people living with diabetes mellitus. 12% of global health expenditure is spent on diabetes. Approximately 46% of people living with diabetes are doing so without a full and proper diagnosis… [Read More]

References

The Invention policy is based on the following References

1-SÖYLEMEZ MEHMET ALİ., A Novel Mechanism between Type II Diabetes Mellitus and Procalcitonin Gene Expression; Molecular Therapy … [Read More]

The inventor

Please click here to read the resume of the inventor.

Email

Copyright@ Mehmet Ali Söylemez